European Journal of Cancer最新文献

{"title":"Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab","authors":"Francesco Cortiula ,&nbsp;Talia Shentzer Kutiel ,&nbsp;Melinda L. Hsu ,&nbsp;Lizza E.L. Hendriks ,&nbsp;Amin H. Nassar ,&nbsp;Mor Moskovitz ,&nbsp;So Yeon Kim ,&nbsp;Matthew M. Mirsky ,&nbsp;Ritujith Jayakrishnan ,&nbsp;Martina Bortolot ,&nbsp;Jessica Saddi ,&nbsp;Paolo Borghetti ,&nbsp;Michelle J. Chung ,&nbsp;Andrea Riccardo Filippi ,&nbsp;Dirk De Ruysscher ,&nbsp;Jair Bar","doi":"10.1016/j.ejca.2025.115302","DOIUrl":"10.1016/j.ejca.2025.115302","url":null,"abstract":"<div><h3>Introduction</h3><div>The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patients, often necessitating subsequent systemic therapy. The only available data about re-challenge immune checkpoint blockers (ICB) in this setting derives from small retrospective series. We evaluated progression free survival (PFS) and overall survival (OS) in patients receiving either ICB-based therapy versus a chemotherapy (CT)-only for disease progression after CRT and durvalumab.</div></div><div><h3>Materials and methods</h3><div>Multicenter retrospective study, conducted across 10 centers in Italy, the USA, Israel, and The Netherlands. Consecutive patients with relapsed NSCLC following CRT and durvalumab were enrolled.</div></div><div><h3>Results</h3><div>A total of 197 patients met the eligibility criteria: 93 received CT ( ± anti-VEGF), and 104 received an ICB-based treatment ( ± CT). The median PFS for patients receiving an ICB-based versus a CT-only regimen was 5.9 (95 % CI 4.3–7.6) versus 4.9 months (95 % CI 3.9–5.8), respectively (p = 0.011, HR: 0.67, 95 % CI 0.49–0.91). The median OS was 14.6 months (95 % CI 9.9–19.4) versus 8.9 (95 % CI 7.4–10.4), respectively (p = 0.005, HR: 0.61, 95 % CI 0.43–0.86). Patients with PFS ≥ 12 months on durvalumab, treated with subsequent ICB or CT median OS was 22.0 (95 % CI: 12.9–31.2) 9.8 months (95 % CI: 4.3–15.2) respectively (p = 0.024). Among patients with a PFS &lt; 12 months on durvalumab there was no significant OS difference between ICB and CT arms.</div></div><div><h3>Conclusions</h3><div>ICB retreatment at disease progression after CRT and durvalumab might offer an OS benefit over CT in patients who do not relapse during durvalumab treatment.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"219 ","pages":"Article 115302"},"PeriodicalIF":7.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143471617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results” [Eur J Cancer 213 (2024):115079]","authors":"Alice Indini ,&nbsp;Fabio Didoné ,&nbsp;Daniela Massi ,&nbsp;Susana Puig ,&nbsp;Jordi Rubio Casadevall ,&nbsp;Damien Bennett ,&nbsp;Alexander Katalinic ,&nbsp;Arantza Sanvisens ,&nbsp;Andrea Ferrari ,&nbsp;Paolo Lasalvia ,&nbsp;Elena Demuru ,&nbsp;Rosalia Ragusa ,&nbsp;Alexandra Mayer-da-Silva ,&nbsp;Marcel Blum ,&nbsp;Mohsen Mousavi ,&nbsp;Claudia Kuehni ,&nbsp;Ana Mihor ,&nbsp;Mario Mandalà ,&nbsp;Annalisa Trama ,&nbsp;EUROCARE-6 Working Group","doi":"10.1016/j.ejca.2025.115295","DOIUrl":"10.1016/j.ejca.2025.115295","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"218 ","pages":"Article 115295"},"PeriodicalIF":7.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05–2018)","authors":"Giuseppe Maglietta ,&nbsp;Angela Damato ,&nbsp;Silvia Finotto ,&nbsp;Marta Mandarà ,&nbsp;Stefano Tamberi ,&nbsp;Salvatore Grisanti ,&nbsp;Matteo Brighenti ,&nbsp;Marcello Tiseo ,&nbsp;Vincenzo Montesarchio ,&nbsp;Annamaria Catino ,&nbsp;Fabio Gelsomino ,&nbsp;Filippo Giovanardi ,&nbsp;Lorenzo Antonuzzo ,&nbsp;Alessandra Romagnani ,&nbsp;Erika Gervasi ,&nbsp;Massimo Di Maio ,&nbsp;Carmine Pinto","doi":"10.1016/j.ejca.2025.115296","DOIUrl":"10.1016/j.ejca.2025.115296","url":null,"abstract":"<div><h3>Background</h3><div>The oral factor Xa inhibitor, edoxaban, is effective and safe in cancer-associated Venous Thromboembolism (VTE) treatment. The EDOI study aims to evaluate compliance and quality of life (QoL) in patients with cancer-associated VTE treated with edoxaban during antineoplastic care.</div></div><div><h3>Material and methods</h3><div>The EDOI was a multicentre phase IV, single-arm study. Patients received edoxaban for at least 6 months. The primary objective was to evaluate the rate and 90 % Confidence Intervals of edoxaban-related adverse events (AEs) with impact on antineoplastic therapy in terms of delays, reduction, or interruption. Mixed models for repeated measure have been adopted to evaluate the secondary endpoint as the change of QoL scores from enrolment to 6 months.</div></div><div><h3>Results</h3><div>From July 2019 to March 2021, 147 patients were enrolled. Edoxaban-related AEs with impact on antineoplastic therapy were observed in 7 patients (4.76 %; 90 %CI 2.23 %-8.94 %). The cumulative incidence of AEs was 2.7 % at 1 month from enrolment. A statistically significant increase (p &lt; 0.05) was observed for mean changes in PACT-Q2 Convenience (+5 points) and Satisfaction (at least +2.5), and reduction of ACTS Burden (at least +1.7) at 1 month. Overall QoL measured by FACT-G shows a mean increase in the first month (+1.3), while decreases in the subsequent 5 months (-2.5).</div></div><div><h3>Conclusion</h3><div>The results of the EDOI Study demonstrate that edoxaban was well tolerated in patients receiving cancer treatment, showing a low rate of AEs with an impact on antineoplastic therapy, mainly within the first 30 days of administration. Lastly, the edoxaban-related AEs did not result in a lower overall QoL.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"219 ","pages":"Article 115296"},"PeriodicalIF":7.6,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine","authors":"Karin P.S. Langenberg ,&nbsp;Sander R. van Hooff ,&nbsp;Bianca Koopmans ,&nbsp;Josephine G.M. Strijker ,&nbsp;Waleed M. Kholosy ,&nbsp;Kimberley Ober ,&nbsp;Danny A. Zwijnenburg ,&nbsp;Jessica J.F. van der Hoek ,&nbsp;Kaylee M. Keller ,&nbsp;Lindy Vernooij ,&nbsp;Linda G. Schild ,&nbsp;Eleonora J. Looze ,&nbsp;Marli E. Ebus ,&nbsp;Anke H.W. Essing ,&nbsp;Paula de Vree ,&nbsp;Michelle L. Tas ,&nbsp;Yvette A.H. Matser ,&nbsp;Judith Wienke ,&nbsp;Richard Volckmann ,&nbsp;Bastiaan B.J. Tops ,&nbsp;Jan J. Molenaar","doi":"10.1016/j.ejca.2025.115275","DOIUrl":"10.1016/j.ejca.2025.115275","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite druggable events to be present in 80 % of neuroblastomapatients within the Princess Máxima Center precision medicine program 'iTHER', clinical uptake of treatment recommendations has been low, and the clinical impact for individual patients remains hard to predict. This stresses the need for a method integrating genomics and transcriptomics with functional approaches into therapeutic decision making.</div></div><div><h3>Methods</h3><div>We aimed to launch an online repository integrating genomics and transcriptomics with high-throughput drug screening (HTS) of nineteen commonly used neuroblastoma cell lines and fifteen neuroblastoma patient-derived organoids (NBL-PDOs). Cell lines, NBL-PDOs and their parental tumors were characterized utilizing (lc)WGS, WES and RNAseq. Cells were exposed to ∼200 compounds. Results were transferred to the R2 visualization platform.</div></div><div><h3>Results</h3><div>A powerful reference set of cell lines is available, reflecting distinct known pharmacologic vulnerabilities. HTS identified additional therapeutic vulnerabilities, such as a striking correlation between a positive mesenchymal signature and sensitivity to BCL2-inhibitor venetoclax. Finally, we explored personalized drug sensitivities within iTHER, demonstrating HTS can support genomic and transcriptomic results, thereby strengthening the rationale for clinical uptake.</div></div><div><h3>Conclusion</h3><div>We established a dynamic publicly available dataset with detailed genomic, transcriptomic, and pharmacological annotation of classical neuroblastoma cell lines as well as novel sharable NBL-PDOs, representing the heterogeneous landscape of neuroblastoma. We anticipate that <em>in vitro</em> drug screening will be complementary to genomic-guided precision medicine by supporting clinical decision making, thereby improving prognosis for all neuroblastoma patients in the future.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"218 ","pages":"Article 115275"},"PeriodicalIF":7.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143402568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy","authors":"Nicolas Cabrit ,&nbsp;Maurice Cheugoua-Zanetsie ,&nbsp;Jayne Tierney ,&nbsp;Pierre Thirion ,&nbsp;Matthew Nankivell ,&nbsp;Kathryn Winter ,&nbsp;Hong Yang ,&nbsp;Bas Wijnhoven ,&nbsp;Dewi Vernerey ,&nbsp;B.Mark Smithers ,&nbsp;Guillaume Piessen ,&nbsp;Magnus Nilsson ,&nbsp;Jurjen Boonstra ,&nbsp;Marc Ychou ,&nbsp;Simon Law ,&nbsp;David Cunningham ,&nbsp;Florent de Vathaire ,&nbsp;Michael Stahl ,&nbsp;Susan Urba ,&nbsp;Michele Valmasoni ,&nbsp;Stefan Michiels","doi":"10.1016/j.ejca.2025.115292","DOIUrl":"10.1016/j.ejca.2025.115292","url":null,"abstract":"<div><h3>Background</h3><div>The use of surrogate endpoints may expedite the reporting of study outcomes of clinical trials. The validity of disease-free survival (DFS) as a surrogate for overall survival (OS) in the neoadjuvant treatment of esophageal (E) or gastroesophageal junctional (GEJ) carcinomas remains uncertain.</div></div><div><h3>Objective</h3><div>To evaluate DFS as a surrogate end-point for OS in E/GEJ using the meta-analytical approach</div></div><div><h3>Design, setting, and participants</h3><div>individual patient data from an international meta-analysis on operable locally advanced E/GEJ, which including randomized trials comparing at least two of the neo-adjuvant treatment strategies: upfront surgery (S), chemotherapy followed by surgery (CS), and/or chemoradiotherapy followed by surgery (CRS).</div></div><div><h3>Main outcomes and measures</h3><div>Individual (Kendall’s tau) and trial-level (R2) correlations between DFS and OS were estimated using a Clayton copula.</div></div><div><h3>Results</h3><div>DFS and OS data were available for a total of 4518 pts: 2222 pts included in CS vs S, 1908 pts in CRS vs S, and 388 in CS vs CRS comparisons. 3440 patients had a DFS event and 3303 patients died. Kendall’s tau was 0.73 [95 % CI 0.71 – 0.75] and R2 trial-level correlation was 0.95 [0.84 – 0.99] for CS vs S, Kendall’s tau was 0.76 [0.74 – 0.77] and R2 was 0.96 [0.87 – 0.99] for CRS vs S, Kendall’s tau was 0.87 [0.78 – 0.92] and R2 was 0.93 [0.43 – 1] for CRS vs CS. In a multistate model, the median time in the recurrence state was shorter in older vs more recent trials: mean time of 10.8 [10.2 – 11.4] vs 16.5 months [15.4–17.6].</div></div><div><h3>Conclusions and relevance</h3><div>DFS is a validated surrogate endpoint for OS in trials evaluating neoadjuvant chemotherapy or chemoradiotherapy in E/GEJ. DFS may be more useful as an endpoint when delays between recurrences and death become larger.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"218 ","pages":"Article 115292"},"PeriodicalIF":7.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143379042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial","authors":"Guilhem Roubaud ,&nbsp;Marie Kostine ,&nbsp;Raymond S. McDermott ,&nbsp;Alice Bernard-Tessier ,&nbsp;Xavier Maldonado ,&nbsp;Marlon Silva ,&nbsp;Aude Fléchon ,&nbsp;Dominik R. Berthold ,&nbsp;Philippe Ronchin ,&nbsp;Bertrand F. Tombal ,&nbsp;Loïc Mourey ,&nbsp;Gwenaëlle Gravis ,&nbsp;Anne Escande ,&nbsp;Sophie Abadie-Lacourtoisie ,&nbsp;Tristan Maurina ,&nbsp;Miguel A. Climent ,&nbsp;Hélène Ribault ,&nbsp;Alberto Bossi ,&nbsp;Stéphanie Foulon ,&nbsp;Karim Fizazi","doi":"10.1016/j.ejca.2025.115293","DOIUrl":"10.1016/j.ejca.2025.115293","url":null,"abstract":"<div><h3>Aim</h3><div>Addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D) improved overall survival in patients with de novo metastatic castration sensitive prostate cancer in the PEACE-1 trial. The protocol was amended during the course of the study to assess whether addition of AAP increases bone loss.</div></div><div><h3>Methods</h3><div>Patients were randomized to receive either ADT + D with or without AAP. Bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip were measured by dual X-ray absorptiometry at baseline, 6, 12, and 24 months (M). T-Scores and mean percent change in BMD values were assessed.</div></div><div><h3>Results</h3><div>With 97 patients treated with AAP and 98 without, the median age was 65 years and 69 patients were ECOG 0 in each arm. Median baseline body mass index was 25.6 and 26.5 kg/m² in patients treated with or without AAP, respectively. Ten and 30 % presented with baseline osteoporosis and osteopenia, respectively. Mean T scores and mean percent changes in BMD measured on three anatomic sites decreased during the first year of treatment in both arms, without difference between arms. At M24, a numerical two-fold increase in patients with osteoporosis was observed in the AAP arm.</div></div><div><h3>Conclusions</h3><div>This is the first prospective assessment of BMD in a randomized trial with an experimental treatment using AAP. Bone loss occurred rapidly in both arms, and addition of AAP did not increase bone loss significantly although a numerically higher rate of osteoporosis was observed at 2 years.</div></div><div><h3>Trial registration</h3><div>NCT01957436.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"218 ","pages":"Article 115293"},"PeriodicalIF":7.6,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Winner and still champion: Nodule volume doubling times","authors":"David F. Yankelevitz,&nbsp;Rowena Yip,&nbsp;Artit Jirapatnakul,&nbsp;Claudia I. Henschke","doi":"10.1016/j.ejca.2024.115184","DOIUrl":"10.1016/j.ejca.2024.115184","url":null,"abstract":"<div><div>There have been enormous advances in the approach to assessing malignancy status of indeterminate pulmonary nodules including risk models, image based biomarkers and numerous types of biologic and molecular markers. All of these have the advantage of guiding further workup once the nodule is identified. The traditional method, especially for smaller nodules relies primarily on assessing whether a nodule changes in size over time and is a feature in virtually every management protocol for both screen detected as well as incidentally detected nodules. Here, the potential downside is that during the waiting period for obtaining a second scan to assess for growth prognosis changes. However, there must be enough of a time delay to overcome potential measurement error. These two features must be balanced for optimal use of this approach. The alternative approaches do not have this inherent delay, however, their usefulness is a balance between the improvement in prognosis by not having any delays versus their potential to produce false positive and false negative results. Currently nodule volumetric approaches, especially for small nodules remains the method of choice for evaluation.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115184"},"PeriodicalIF":7.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers","authors":"Sait Kitapli,&nbsp;Ali Alkan,&nbsp;Ozgur Tanriverdi","doi":"10.1016/j.ejca.2024.115188","DOIUrl":"10.1016/j.ejca.2024.115188","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115188"},"PeriodicalIF":7.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers","authors":"Ziyi Wang,&nbsp;Zihan Wang","doi":"10.1016/j.ejca.2024.115187","DOIUrl":"10.1016/j.ejca.2024.115187","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115187"},"PeriodicalIF":7.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","authors":"Dirk Tomsitz ,&nbsp;Ulrich Grabmaier ,&nbsp;Judith Spiro ,&nbsp;Leo Nicolai ,&nbsp;Lars E. French ,&nbsp;Steffen Massberg ,&nbsp;Lucie Heinzerling","doi":"10.1016/j.ejca.2024.115186","DOIUrl":"10.1016/j.ejca.2024.115186","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitor (ICI)-induced Myocarditis (irMyocarditis) is a rare adverse event with a high mortality rate of 40–50 % and which is mostly not diagnosed until clinical symptoms emerge.</div></div><div><h3>Objectives</h3><div>This study aims to screen patients for irMyocarditis using high-sensitivity cardiac troponin-T (hs-TnT) before and regularly during therapy with ICI.</div></div><div><h3>Methods</h3><div>A cohort of 280 cancer patients were prospectively screened for levels of hs-TnT at baseline and prior to every ICI infusion. In case of elevation of hs-TnT, patients were referred for further work-up.</div></div><div><h3>Results</h3><div>In total, 196 patients exhibited a baseline hs-TnT ≤ 14 ng/l (99th percentile concentration for general population; group A) and 84 patients a hs-TnT &gt; 14 ng/l at baseline (group B). An increase of hs-TnT during ICI-treatment was observed in 56 out of 196 (27.6 %) and 56 out of 84 patients (66.7 %) in group A and B. Cardiovascular assessment was performed in 11.2 % and 27.4 % of patients, respectively, and 4.1 % and 9.5 % of patients were diagnosed with irMyocarditis and treated with corticosteroids. No fatalities occurred in any of the 16 irMyocarditis patients. Defining a threshold with the highest sensitivity and maximum specificity in receiver-operating characteristics curves, identified a limit of 22 ng/l (group A) and 60 ng/l (group B) hs-TnT, associated with a sensitivity of 100 % in both and a specificity of 91.0 % and 89.6 %, respectively, to detect irMyocarditis.</div></div><div><h3>Conclusion</h3><div>Screening of hs-TnT can identify irMyocarditis early and lead to reduction of MACE and mortality risk through interruption of ICI-treatment and prompt therapy with corticosteroids.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115186"},"PeriodicalIF":7.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}